BRIEF-Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Reuters2026/09/23 11:05Oruka Therapeutics Inc ORKA.O:
ORUKA THERAPEUTICS ANNOUNCES POSITIVE WEEK 28 DATA FOR ORKA-001 FROM THE ONGOING EVERLAST-A TRIAL SHOWING DEEPENING OF RESPONSES WITHOUT ADDITIONAL DOSING
ORUKA THERAPEUTICS - ORKA-001 MAINTAINS FAVORABLE SAFETY AND TOLERABILITY PROFILE THROUGH WEEK 28
ORUKA THERAPEUTICS - TWO SERIOUS ADVERSE EVENTS REPORTED, NEITHER DEEMED DRUG RELATED
ORUKA THERAPEUTICS - 16-WEEK EVERLAST-B DATA EXPECTED IN FOURTH QUARTER 2026
ORUKA THERAPEUTICS - 52-WEEK EVERLAST-A DATA EXPECTED IN DECEMBER 2026
Source text: ID:nGNX10yvmc
Further company coverage: ORKA.O
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
